. Author manuscript; available in PMC: 2024 May 1.

Published in final edited form as: Infect Control Hosp Epidemiol. 2022 Feb 15;44(5):794–797. doi: 10.1017/ice.2022.9

Table 2.

Percentage of Isolates Not Susceptible to Trimethoprim-Sulfamethoxazole Among Methicillin-resistant Staphylococcus aureus (MRSA) Associated with Surgical Site Infections (SSIs), Central-Line–Associated Bloodstream Infections (CLABSIs), and Catheter-Associated Urinary Tract Infections (CAUTIs)—National Healthcare Safety Network, 2012 and 2018

Type	Continuously Reporting Facilities^a	2012 No. Not Susceptible/No. Tested (% Not Susceptible)	2018 No. Not Susceptible/No. Tested (% Not Susceptible)	2018 vs 2012^b, Absolute % Difference (95% CI)
Overall	3,135	129/3,550 (3.6)	146/2,642 (5.5)	1.9 (0.8–3.0)^c
CAUTI	2,638	12/186 (6.5)	5/75 (6.7)	0.2 (−6.4 to 6.9)
CLABSI	2,671	32/637 (5.0)	17/318 (5.3)	0.3 (−2.7–3.3)
SSI	2,753	85/2,727 (3.1)	124/2,249 (5.5)	2.4 (1.2–3.5)^c

Note. CI, confidence interval; CAUTI, catheter-associated urinary tract infections; CLABSI, central-line–associated bloodstream infections; SSI, surgical site infections.

Continuous reporting facilities were defined as follows: (1) for CLABSIs, hospitals that reported at least 1 month of in-plan CLABSI data, in both 2012 and 2018, for the same location; (2) for CAUTIs, hospitals that reported at least 1 month of in-plan CAUTI data, in both 2012 and 2018, for the same location; and (3) for SSIs, hospitals that reported at least 1 month of in-plan SSI data, in both 2012 and 2018, for the same procedure code.

95% confidence intervals for the difference between years were calculated using the Wald statistic.

Statistically significant difference.